Positive Beta Site Results for Sequenom's iPLEX™ Assay Trigger Multiple Sales
News Sep 22, 2005
Sequenom, Inc. has announced the purchase of multiple MassARRAY® Compact systems, following the completion of two iPLEX assay beta site programs.
The Broad Institute of MIT and Harvard and the Wellcome Trust Sanger Institute each purchased two systems based on positive results using the iPLEX multiplexing application for various fine mapping projects.
"Sequenom's iPLEX assay is very useful for evaluating targeted sets of SNPs," stated Stacey Gabriel, Ph.D., Director of the Genetic Analysis Platform of the Broad Institute.
"It also expedites follow up work in the validation of genome scan results and we hope it will prove valuable in up-coming cohort studies involving diabetes and other complex diseases."
The Broad Institute is home to the first national center for high-throughput genotyping dedicated solely to large-scale SNP analysis.
Researchers used the iPLEX assay for fine mapping and biomarker validation of an international consortium study on Type 2 diabetes.
"We use the MassARRAY system because it's very flexible, allowing us to conduct projects that require typing of one SNP up to several hundred," stated Panos Deloukas, Ph.D., Senior Investigator, Division of Medical Genetics, the Wellcome Trust Sanger Institute.
"With the advent of iPLEX, the system became more competitive for fine mapping studies, offering higher levels of multiplexing and maintaining data quality."
"We are very pleased by the decision of both the Sanger Institute and the Broad Institute to adopt the iPLEX assay for use with the MassARRAY Compact for fine mapping studies," said Harry Stylli, Ph.D., MBA, Sequenom's President and Chief Executive Officer.
"The promising results of the beta site programs serve to further position Sequenom as a leading provider of solutions for SNP genotyping studies in the fast growing fine mapping segment of the genomic analysis market."
Analytical Tool Predicts Disease-Causing GenesNews
Predicting genes that can cause disease due to the production of truncated or altered proteins that take on a new or different function, rather than those that lose their function, is now possible thanks to an international team of researchers that has developed a new analytical tool to effectively and efficiently predict such candidate genes.
Single Gene Change in Gut Bacteria Alters Host MetabolismNews
Scientists have found that deleting a single gene in a particular strain of gut bacteria causes changes in metabolism and reduced weight gain in mice. The research provides an important step towards understanding how the microbiome – the bacteria that live in our body – affects metabolism.READ MORE
Gotta Sample 'Em All! Underwater Pokéball Captures Ocean LifeNews
A new device developed by Wyss Institute reseachers safely traps delicate sea creatures inside a folding polyhedral enclosure and lets them go without harm using a novel, origami-inspired design. The ultimate aim is to allow the sea creatures to be (gently) analyzed in high detail.READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018